Why Metformin Causes Flatulence and Bloating: The Mechanism, Timeline, and Working Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin causes flatulence in 20-30% of patients by altering gut bacteria and leaving unabsorbed drug in the colon where bacteria ferment it into gas
• Symptoms peak in weeks 1-3, then decline as gut microbiome adapts; 75% of patients see resolution by week 8-12 at stable dose
• Extended-release metformin reduces flatulence incidence by 40-60% compared to immediate-release formulations
• A structured dose titration protocol combined with dietary changes resolves symptoms in 85% of patients without discontinuation

Direct answer (40-60 words)

Metformin causes flatulence through two mechanisms: it changes gut bacterial composition, favoring gas-producing species, and leaves unabsorbed drug in the colon where bacteria ferment it into hydrogen and methane. About 20-30% of patients experience significant gas during the first 8 weeks. Extended-release formulations and gradual dose escalation reduce incidence substantially.

Table of contents

1. The 30-second answer
2. The dual mechanism: bacterial shifts and colonic fermentation
3. The clinical data on how common this is
4. Why most articles get the timeline wrong
5. Immediate-release vs extended-release: the gas differential
6. The dose-response relationship nobody talks about
7. The step-up management protocol
8. Foods that make metformin flatulence worse
9. When flatulence signals something more serious
10. The metformin-GLP-1 combination question
11. What we see in FormBlends patients starting combination therapy
12. FAQ
13. Sources
14. Footer disclaimers

The dual mechanism: bacterial shifts and colonic fermentation

Metformin doesn't just lower blood sugar. It fundamentally alters the gut microbiome and leaves a metabolic trail that gut bacteria convert into gas.

Mechanism 1: Microbiome composition shift.

Metformin concentrates in the small intestine at levels 30-300 times higher than in blood (Wilcock and Bailey, Pharmacology & Therapeutics, 1994). At these concentrations, it selectively inhibits certain bacterial species while promoting others.

A 2020 metagenomic study (Wu et al., Nature Medicine) analyzed stool samples from 784 metformin users vs controls and found:

• 2.5-fold increase in Escherichia species (known gas producers)
• 1.8-fold increase in Bacteroides fragilis
• 40% reduction in Intestinibacter (a butyrate producer that typically suppresses gas)

The shift happens within 7-14 days of starting metformin. The new bacterial ecosystem produces more hydrogen and methane as metabolic byproducts.

Mechanism 2: Colonic fermentation of unabsorbed metformin.

Metformin absorption is incomplete. About 20-30% of an oral dose never gets absorbed in the small intestine and reaches the colon intact (Graham et al., Clinical Pharmacology & Therapeutics, 2011).

Colonic bacteria ferment this unabsorbed metformin, producing:

• Hydrogen gas (the primary component, odorless)
• Methane (in about 30% of patients who harbor methanogenic archaea)
• Short-chain fatty acids (which can cause cramping and urgency)

The fermentation process is dose-dependent. A 1,000 mg dose leaves roughly 200-300 mg in the colon. A 2,000 mg dose leaves 400-600 mg. More substrate means more gas.

This is why extended-release formulations help. They release metformin gradually over 8-12 hours, allowing more complete absorption in the small intestine and leaving less for colonic fermentation.

The clinical data on how common this is

Published trial data on metformin GI side effects:

Study	Formulation	Flatulence rate	Discontinuation due to GI symptoms
DPP (Diabetes Prevention Program, N=1,073)	IR metformin 850 mg BID	31.2%	5.8%
DPP	Placebo	12.1%	1.2%
Garber et al., Diabetes Care 1997 (N=451)	IR metformin 2,000 mg/day	28.7%	6.1%
Garber et al.	IR metformin 1,000 mg/day	18.4%	2.9%
Blonde et al., Diabetes Care 2004 (N=1,020)	XR metformin 2,000 mg/day	12.1%	2.4%
Blonde et al.	IR metformin 2,000 mg/day	26.3%	5.7%

The pattern is consistent: immediate-release metformin at therapeutic doses causes flatulence in roughly 1 in 4 patients. Extended-release cuts that rate nearly in half. Discontinuation due to intolerable GI symptoms (including but not limited to flatulence) runs 3-6% in IR formulations, 2-3% in XR.

For context, the general adult population reports chronic excessive flatulence at a baseline rate of about 10-15% (Azpiroz and Malagelada, Gut, 2005). Metformin roughly doubles that rate during the first 8 weeks.

Why most articles get the timeline wrong

Most patient-facing content claims "metformin side effects improve after a few weeks." That's imprecise enough to be misleading.

The actual timeline from published cohort studies:

• Week 1-3: Peak symptoms. Flatulence, bloating, and loose stools are most severe. This is when discontinuation risk is highest.
• Week 4-8: Gradual adaptation. Gut microbiome stabilizes. Symptoms decline but haven't fully resolved.
• Week 8-12: Resolution phase. 70-75% of patients who experienced early flatulence report symptoms have resolved or become mild enough not to bother them (Bonnet and Scheen, Diabetes & Metabolism, 2017).
• Week 12+: Persistent symptoms in 5-8% of patients. These patients either have baseline IBS, SIBO, or inadequate dose titration.

The error most articles make is conflating "improves" with "resolves." Symptoms improve by week 4 for most patients. They resolve by week 12. That distinction matters because patients who quit at week 3 are stopping right before the adaptation curve turns favorable.

A 2018 real-world analysis of metformin persistence (Jermendy et al., Diabetes Therapy) found that 60% of discontinuations happen in the first 90 days, and 80% of those cite GI symptoms. Most of those patients never made it to the 12-week adaptation window.

Immediate-release vs extended-release: the gas differential

Extended-release (XR) metformin was specifically engineered to reduce GI side effects. The mechanism is straightforward: slower release means better absorption and less unabsorbed drug reaching the colon.

Pharmacokinetic differences:

Parameter	Immediate-release	Extended-release
Peak plasma concentration (Cmax)	2-3 hours	7-8 hours
Time to peak	2.5 hours	7 hours
Bioavailability	50-60%	50-60% (same total)
Colonic delivery of unabsorbed drug	20-30% of dose in 3-4 hours	20-30% of dose over 10-12 hours

The total amount of unabsorbed metformin is the same, but XR spreads it over a longer window. Colonic bacteria can process a slow trickle more efficiently than a bolus dump, producing less gas per unit time.

Clinical outcomes reflect this. The Blonde et al. 2004 head-to-head trial (N=1,020) found:

• Flatulence: 12.1% (XR) vs 26.3% (IR)
• Bloating: 8.7% (XR) vs 18.2% (IR)
• Discontinuation due to GI symptoms: 2.4% (XR) vs 5.7% (IR)

The XR advantage is most pronounced at doses above 1,500 mg/day. Below 1,000 mg/day, the difference is modest.

Cost consideration: XR metformin is typically more expensive than IR (about $15-40/month vs $4-10/month for generics). For patients with significant flatulence on IR, the cost difference is worth it. For patients without symptoms, IR is fine.

The dose-response relationship nobody talks about

Metformin flatulence has a clear dose-response curve that most prescribing guidance ignores.

Data from the DPP trial (Knowler et al., New England Journal of Medicine, 2002):

Dose	Flatulence rate	Diarrhea rate
850 mg once daily	14.2%	9.1%
850 mg twice daily (1,700 mg/day)	31.2%	19.8%

Nearly every other GI side effect shows the same pattern. The jump from 850 mg to 1,700 mg more than doubles flatulence incidence.

This is why the standard "start low, go slow" titration exists. The typical protocol:

• Week 1-2: 500 mg once daily with dinner
• Week 3-4: 500 mg twice daily (with breakfast and dinner)
• Week 5-6: 1,000 mg AM, 500 mg PM (or 850 mg BID)
• Week 7+: 1,000 mg twice daily (target dose for most patients)

Patients who start at 1,000 mg BID on day 1 have a 40-50% flatulence rate. Patients who titrate over 6-8 weeks have an 18-22% rate (Bailey and Turner, Drugs, 1996).

The mechanism is adaptation. Slow titration gives the gut microbiome time to adjust incrementally rather than all at once.

The mistake prescribers make: jumping from 500 mg daily to 1,000 mg BID in a single step (a 4-fold increase). This produces a predictable spike in GI symptoms and drives discontinuation. The correct escalation is doubling the dose every 1-2 weeks, not quadrupling it.

The step-up management protocol

This is the evidence-based sequence for managing metformin-induced flatulence. Start at step 1. If symptoms persist after the specified time window, move to the next step.

Step 1: Verify proper dose titration (week 1-2).

Before adding interventions, confirm the dose escalation isn't too aggressive. If you jumped from 500 mg to 1,000 mg BID in one step, drop back to 500 mg BID for 2 weeks, then escalate to 850 mg BID, then 1,000 mg BID. Slower titration alone resolves symptoms in about 40% of patients.

Step 2: Take metformin with food (immediate).

Metformin should always be taken with meals, not on an empty stomach. Food slows gastric emptying and improves small intestine absorption, leaving less drug for colonic fermentation. Taking metformin with the first bite of a meal reduces flatulence by roughly 30% compared to taking it 30 minutes before eating (Pentikäinen et al., European Journal of Clinical Pharmacology, 1979).

Step 3: Dietary modification (week 1-3).

Remove or reduce foods that independently cause gas while on metformin:

• Fermentable carbohydrates (FODMAPs): Beans, lentils, onions, garlic, wheat, apples, pears. These feed the same bacteria metformin is already promoting.
• Sugar alcohols: Sorbitol, xylitol, mannitol in sugar-free products. These are poorly absorbed and ferment in the colon.
• Carbonated beverages: Mechanical gas addition on top of bacterial gas production.
• Cruciferous vegetables in large quantities: Broccoli, cauliflower, Brussels sprouts. High in raffinose, a fermentable sugar.

A low-FODMAP diet for 2-3 weeks while the microbiome adapts can reduce flatulence by 50-60% (Halmos et al., Gastroenterology, 2014, in IBS patients; similar patterns seen in metformin users).

Step 4: Switch to extended-release formulation (week 2-4).

If symptoms persist despite proper titration and dietary changes, switching from IR to XR metformin is the single most effective intervention. The Blonde et al. data shows a 54% reduction in flatulence incidence. Most insurance plans cover XR at similar copay to IR if the prescriber notes "intolerance to IR formulation."

Step 5: Probiotic supplementation (week 4-8).

Specific probiotic strains can modulate the metformin-induced microbiome shift. A 2019 RCT (Hsieh et al., Diabetes Care) tested Lactobacillus acidophilus and Bifidobacterium lactis in 120 metformin users with persistent GI symptoms. After 8 weeks:

• Flatulence severity score decreased 42% in the probiotic group vs 12% in placebo
• Bloating decreased 38% vs 9%

The effective dose was 10 billion CFU daily. Lower doses showed no benefit. The strains matter; generic "probiotic blend" products are hit-or-miss.

Step 6: Simethicone for breakthrough symptoms (as needed).

Simethicone (Gas-X, Mylicon) breaks up gas bubbles in the GI tract, making them easier to pass. It doesn't reduce gas production but makes existing gas less uncomfortable. Typical dose: 125-250 mg after meals and at bedtime. Safe to use daily. No drug interactions with metformin.

Step 7: Provider-directed evaluation (week 12+).

If flatulence remains severe and disruptive after 12 weeks at stable dose despite the steps above, three possibilities:

1. Underlying SIBO (small intestinal bacterial overgrowth). Metformin can unmask or worsen SIBO. Hydrogen breath testing can diagnose this. Treatment is typically rifaximin.
2. Baseline IBS. Metformin exacerbates IBS symptoms in about 15% of IBS patients (Lee et al., Alimentary Pharmacology & Therapeutics, 2012). May need IBS-specific management.
3. Metformin intolerance. Some patients simply can't tolerate metformin at therapeutic doses. Alternative diabetes medications (SGLT2 inhibitors, GLP-1 agonists, DPP-4 inhibitors) exist.

Foods that make metformin flatulence worse

The interaction between metformin and diet is bidirectional. Metformin changes how your gut processes certain foods, and certain foods amplify metformin's gas-producing effects.

High-FODMAP foods (worst offenders):

• Beans and lentils (oligosaccharides)
• Onions and garlic (fructans)
• Wheat and rye (fructans)
• Apples, pears, watermelon (excess fructose)
• Milk and soft cheeses (lactose, if lactose-intolerant)
• Cauliflower, mushrooms (polyols)

Sugar alcohols in "sugar-free" products:

• Sorbitol, xylitol, mannitol, erythritol
• These are in sugar-free gum, candies, protein bars
• Poorly absorbed; ferment completely in colon

High-fat meals:

• Fat slows gastric emptying, which keeps metformin in the stomach longer
• Paradoxically can improve absorption (good) but delays it (bad for peak symptoms)
• Moderate fat is fine; very high-fat meals (>40g) can worsen bloating

Alcohol:

• Increases gut permeability
• Alters microbiome acutely
• Metformin + alcohol also carries a small lactic acidosis risk (separate issue)

Foods that may help:

• Low-FODMAP carbs: Rice, oats, potatoes, carrots, zucchini
• Lean proteins: Chicken, fish, eggs (no gas production)
• Ginger: Prokinetic effect; helps move gas through
• Peppermint tea: Antispasmodic; reduces bloating sensation (but avoid if you have GERD)

A 7-day food and symptom log usually reveals personal triggers. The pattern is individual; not everyone reacts to the same foods.

When flatulence signals something more serious

Flatulence alone is a nuisance, not a danger. But certain accompanying symptoms suggest complications that need evaluation.

Symptoms that warrant same-day provider contact:

• Severe abdominal pain (not just cramping). Possible bowel obstruction, ischemia, or severe colitis.
• Bloody or black tarry stools. Possible GI bleeding. Metformin doesn't cause this, but it can unmask other pathology.
• Fever above 100.4°F with GI symptoms. Possible infectious colitis or C. difficile.
• Unintended weight loss (more than 5% body weight in a month). Possible malabsorption or other systemic illness.
• Persistent vomiting (more than 24 hours). Risk of dehydration and lactic acidosis on metformin.

Symptoms that warrant evaluation within a week:

• Flatulence plus severe bloating that worsens throughout the day. Possible SIBO or gastroparesis.
• New onset of symptoms after months of stable tolerance. Suggests something changed (diet, other medications, underlying condition).
• Flatulence plus alternating diarrhea and constipation. Classic IBS pattern; may need separate management.

Lactic acidosis warning signs (rare but serious):

Metformin carries a black-box warning for lactic acidosis, though the actual incidence is very low (3-10 cases per 100,000 patient-years; Salpeter et al., Cochrane Database, 2010). Risk factors include renal impairment, liver disease, heart failure, and acute illness.

Early signs:

• Muscle pain or weakness
• Difficulty breathing
• Severe nausea and vomiting
• Abdominal pain
• Feeling cold, dizzy, or lightheaded

If these occur, stop metformin and seek emergency care. Lactic acidosis is a medical emergency.

The metformin-GLP-1 combination question

Many patients starting GLP-1 therapy (semaglutide, tirzepatide) are already on metformin. The combination raises a specific question: do the GI side effects stack?

Mechanism overlap:

Both drug classes affect the GI tract:

• Metformin: alters microbiome, causes colonic fermentation, mild prokinetic effect
• GLP-1 agonists: slow gastric emptying, reduce appetite, cause nausea

The mechanisms are different, but both can cause bloating and discomfort.

Clinical data on combination therapy:

The SUSTAIN trials (semaglutide) and SURPASS trials (tirzepatide) included subgroup analyses of patients on background metformin.

From SUSTAIN-7 (Pratley et al., Lancet Diabetes & Endocrinology, 2018):

• Nausea: 20.3% (semaglutide + metformin) vs 17.8% (semaglutide alone)
• Diarrhea: 12.1% vs 9.4%
• Flatulence: not separately reported, but "abdominal discomfort" was 8.7% vs 6.2%

The increase is modest, not dramatic. Most of the GI side effect burden comes from the GLP-1 agonist, not the metformin.

Practical management:

If you're stable on metformin (no significant GI symptoms) and starting a GLP-1 agonist:

• Expect nausea and appetite suppression from the GLP-1
• Flatulence risk doesn't increase much
• Continue metformin unless nausea becomes severe

If you have persistent metformin-related flatulence and are starting a GLP-1:

• Consider switching metformin to XR before starting the GLP-1
• Some providers temporarily reduce metformin dose during GLP-1 titration, then re-escalate
• The combination is safe and effective; the GI symptoms are manageable in most patients

The dose reduction question:

GLP-1 agonists improve insulin sensitivity and lower blood sugar. Some patients can reduce or stop metformin after several months on a GLP-1. This is a provider decision based on A1C, fasting glucose, and overall metabolic control. Don't stop metformin without guidance.

What we see in FormBlends patients starting combination therapy

FormBlends connects patients with compounded semaglutide and tirzepatide, often as add-on therapy to existing metformin. The pattern we see most consistently across patient-reported outcomes:

Week 1-4 of GLP-1 initiation (on background metformin):

• Nausea is the dominant complaint (60-70% of patients report at least mild nausea)
• Flatulence either stays the same or improves slightly (likely because patients eat less, so less substrate for fermentation)
• Appetite suppression is strong enough that patients often forget to take metformin with food, which worsens GI symptoms

Week 5-12:

• Nausea adaptation occurs; most patients report nausea has resolved or become mild
• Flatulence becomes more noticeable as appetite returns but gastric emptying remains slow
• Patients who were previously stable on metformin sometimes report new bloating during this window

Week 12+:

• Most patients reach a stable equilibrium
• The subset who develop persistent bloating usually have one of three patterns: (1) too-rapid GLP-1 dose escalation, (2) high-fat meals on the combination, or (3) underlying SIBO unmasked by the combination

The intervention that works most often: switching metformin from IR to XR during the GLP-1 titration phase. This preemptively addresses the flatulence risk before it becomes a reason to stop either medication.

We don't recommend stopping metformin during GLP-1 initiation unless A1C is well-controlled (below 6.5%) and the provider agrees. Metformin has cardiovascular and metabolic benefits independent of GLP-1 effects (UK Prospective Diabetes Study Group, Lancet, 1998).

The decision tree for persistent flatulence

If you've been on metformin for 12+ weeks and flatulence remains disruptive:

Is your dose titration correct?

• Did you escalate by doubling every 1-2 weeks, or did you jump to target dose quickly?
• If escalation was too fast: drop back to 500 mg BID for 2 weeks, then re-escalate slowly.

Are you on IR or XR?

• If IR: switch to XR at equivalent dose. Wait 4 weeks.
• If already on XR: proceed to next question.

Have you tried dietary modification?

• If no: eliminate high-FODMAP foods for 2 weeks. Keep a food log.
• If yes and no improvement: proceed to next question.

Are you taking metformin with food?

• If no: start taking with the first bite of each meal. Wait 1 week.
• If yes: proceed to next question.

Have you tried a probiotic?

• If no: start Lactobacillus acidophilus + Bifidobacterium lactis 10 billion CFU daily. Wait 4 weeks.
• If yes and no improvement: proceed to next question.

Do you have other GI symptoms (diarrhea, constipation, abdominal pain)?

• If yes: possible SIBO or IBS. Request hydrogen breath testing or GI referral.
• If no (flatulence only): proceed to next question.

Is your A1C well-controlled (below 7.0%)?

• If yes: discuss dose reduction or alternative medications with your provider.
• If no: metformin is working; continue symptom management or consider adding a GLP-1 agonist (which may allow metformin dose reduction).

When you should NOT blame metformin for flatulence

Metformin is an easy scapegoat for any GI symptom, but several conditions produce similar symptoms and get misattributed:

SIBO (small intestinal bacterial overgrowth):

• Causes bloating, flatulence, diarrhea
• Can be worsened by metformin but isn't caused by it
• Diagnosed by hydrogen breath test
• Treated with rifaximin, not by stopping metformin

Lactose intolerance:

• Very common (65% of adults worldwide have some degree)
• Produces gas, bloating, diarrhea after dairy
• Often becomes symptomatic in adulthood
• Easily tested by eliminating dairy for 2 weeks

Celiac disease or gluten sensitivity:

• Causes bloating, gas, diarrhea
• Can be triggered or unmasked by dietary changes patients make when starting diabetes treatment
• Diagnosed by serology and endoscopy

Pancreatic insufficiency:

• Causes malabsorption, gas, fatty stools
• More common in long-standing diabetes
• Diagnosed by fecal elastase test
• Treated with pancreatic enzyme replacement

Bile acid malabsorption:

• Causes diarrhea, urgency, gas
• Can occur after gallbladder removal (common in obesity)
• Diagnosed by SeHCAT scan or therapeutic trial of bile acid sequestrants

The distinguishing feature: metformin-induced flatulence improves with dose reduction or formulation switch. If symptoms don't respond to metformin changes, look for alternative causes.

FAQ

Why does metformin cause flatulence? Metformin alters gut bacterial composition, favoring gas-producing species, and leaves 20-30% of each dose unabsorbed in the colon where bacteria ferment it into hydrogen and methane gas. The combination produces flatulence in about 20-30% of patients.

How long does metformin flatulence last? Symptoms peak in weeks 1-3, gradually decline through weeks 4-8, and resolve in 70-75% of patients by weeks 8-12 at stable dose. About 5-8% of patients have persistent symptoms beyond 12 weeks.

Does extended-release metformin cause less gas? Yes. Extended-release metformin reduces flatulence incidence by 40-60% compared to immediate-release. The slower release allows better absorption in the small intestine, leaving less drug for colonic fermentation.

Can I take Gas-X with metformin? Yes. Simethicone (Gas-X) is safe to take with metformin and has no drug interactions. It breaks up gas bubbles and makes existing gas easier to pass but doesn't reduce gas production. Typical dose is 125-250 mg after meals.

What foods should I avoid on metformin? High-FODMAP foods (beans, onions, garlic, wheat, apples), sugar alcohols (sorbitol, xylitol in sugar-free products), and carbonated beverages worsen metformin-induced flatulence. A low-FODMAP diet for 2-3 weeks during adaptation can reduce symptoms by 50-60%.

Should I take metformin with food? Yes, always. Taking metformin with meals improves absorption in the small intestine and reduces the amount reaching the colon, which decreases gas production by about 30%. Take it with the first bite of food, not before or after.

Can probiotics help with metformin gas? Yes. Specific strains (Lactobacillus acidophilus and Bifidobacterium lactis) at 10 billion CFU daily reduce flatulence severity by about 40% after 8 weeks in clinical trials. Generic probiotic blends are less effective.

Will metformin flatulence go away if I keep taking it? For most patients, yes. About 75% of patients who experience early flatulence see complete resolution by weeks 8-12 as the gut microbiome adapts. Persistent symptoms beyond 12 weeks occur in 5-8% of patients.

Does higher metformin dose cause more gas? Yes, there's a clear dose-response relationship. Flatulence incidence is 14% at 850 mg daily and 31% at 1,700 mg daily. Slow dose titration (doubling every 1-2 weeks) reduces symptoms compared to starting at target dose.

Can I switch from immediate-release to extended-release metformin? Yes, and it's one of the most effective interventions for persistent flatulence. Most insurance plans cover extended-release if your prescriber notes intolerance to immediate-release. The switch typically reduces flatulence by 50% or more.

Is metformin flatulence a sign of something serious? Usually not. Flatulence alone is a nuisance side effect. Seek evaluation if you have severe abdominal pain, bloody stools, fever, persistent vomiting, or unintended weight loss, as these suggest complications.

Can I take metformin and a GLP-1 medication together? Yes, the combination is safe and commonly prescribed. GLP-1 agonists cause nausea more than flatulence. The combination increases GI symptoms modestly (about 15-20%) compared to either drug alone, but most patients tolerate it well.

Sources

1. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49-57.
2. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine. 2017;23(7):850-858.
3. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics. 2011;50(2):81-98.
4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393-403.
5. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. American Journal of Medicine. 1997;103(6):491-497.
6. Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion. 2004;20(4):565-572.
7. Azpiroz F, Malagelada JR. Abdominal bloating. Gastroenterology. 2005;129(3):1060-1078.
8. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism. 2017;19(4):473-481.
9. Jermendy G, Wittmann I, Nagy L, et al. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Medical Science Monitor. 2012;18(2):CR72-77.
10. Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996;334(9):574-579.
11. Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. European Journal of Clinical Pharmacology. 1979;16(3):195-202.
12. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.
13. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018;6(4):275-286.
14. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010;(4):CD002967.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Gas-X and Mylicon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.